Xspray Pharma Overview
- Year Founded
-
2003

- Status
-
Public
- Employees
-
24

- Stock Symbol
-
XSPRAY

- Share Price
-
$2.92
- (As of Monday Closing)
Xspray Pharma General Information
Description
XSpray Pharma AB is a pharmaceutical company focused on developing improved PKIs for cancer treatment, leveraging its proprietary HyNap technology platform. The company aims to enhance clinical outcomes for cancer patients by improving the efficacy, safety, and patient experience of existing cancer therapies. Its product portfolio includes Dasynoc and other product candidates in different stages of development such as XS003 nilotinib, XS008 axitinib, and XS00Y.
Contact Information
Website
www.xspraypharma.comCorporate Office
- Scheeles väg 2
- 171 65 Solna
- Sweden
Corporate Office
- Scheeles väg 2
- 171 65 Solna
- Sweden
Xspray Pharma Timeline
Xspray Pharma Stock Performance
As of 10-Feb-2025, Xspray Pharma’s stock price is $2.92. Its current market cap is $108M with 34.2M shares.
(As of Monday Closing)
Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
---|---|---|---|---|---|---|
$2.92 | $3.25 | $2.56 - $8.41 | $108M | 34.2M | 36K | -$0.74 |
Xspray Pharma Financials Summary
As of 30-Sep-2024, Xspray Pharma has a trailing 12-month revenue of null.
In Thousands, USD |
TTM 30-Sep-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 |
---|---|---|---|---|
EV | 157,362 | 113,032 | 115,661 | 122,316 |
Revenue | 0 | 0 | 0 | 0 |
EBITDA | (23,862) | (16,233) | (12,178) | (10,373) |
Net Income | (24,466) | (16,903) | (12,979) | (11,260) |
Total Assets | 66,182 | 76,573 | 56,120 | 68,831 |
Total Debt | 3,331 | 3,683 | 204 | 357 |
Xspray Pharma Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
Xspray Pharma Patents
Xspray Pharma Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
US-20220233532-A1 | Fast dissolving pharmaceutical compositions | Active | 21-Jan-2021 | ||
US-11529351-B2 | Fast dissolving pharmaceutical compositions | Active | 21-Jan-2021 | ||
US-20230121325-A1 | Fast dissolving pharmaceutical compositions | Pending | 21-Jan-2021 | ||
EP-4281047-A1 | Fast dissolving pharmaceutical compositions of dasatinib | Pending | 21-Jan-2021 | ||
US-20240024248-A1 | Fast dissolving pharmaceutical compositions | Pending | 21-Jan-2021 | A61K9/2866 |
Xspray Pharma Signals
Xspray Pharma Investors
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|
Xspray Pharma ESG
Risk Overview
Risk Rating
Updated June, 07, 2023
30.6 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 15,120
Rank
Percentile

Pharmaceuticals
Industry
of 853
Rank
Percentile

Pharmaceuticals
Subindustry
of 425
Rank
Percentile

Xspray Pharma FAQs
-
When was Xspray Pharma founded?
Xspray Pharma was founded in 2003.
-
Where is Xspray Pharma headquartered?
Xspray Pharma is headquartered in Solna, Sweden.
-
What is the size of Xspray Pharma?
Xspray Pharma has 24 total employees.
-
What industry is Xspray Pharma in?
Xspray Pharma’s primary industry is Drug Discovery.
-
Is Xspray Pharma a private or public company?
Xspray Pharma is a Public company.
-
What is Xspray Pharma’s stock symbol?
The ticker symbol for Xspray Pharma is XSPRAY.
-
What is the current stock price of Xspray Pharma?
As of 10-Feb-2025 the stock price of Xspray Pharma is $2.92.
-
What is the current market cap of Xspray Pharma?
The current market capitalization of Xspray Pharma is $108M.
-
What is Xspray Pharma’s annual earnings per share (EPS)?
Xspray Pharma’s EPS for 12 months was -$0.74.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »